COMBI-OGAB
Live / Registered — Registered (as of 28 May 2024)
What this means for you
Registered since 28 May 2024. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 79372347
- Registration number
- 7394363
- Mark type
- Stylized text
- Filed
- 31 Mar 2023
- Published for opposition
- 12 Mar 2024
- Registered
- 28 May 2024
Goods and services
- Class 042 — Scientific and technological services: Research and development relating to DNA synthesis technology; technical advisory services relating to DNA synthesis technology; research and development relating to production and analysis of virus vector; technological advisory services relating to production and analysis of virus vector; research and development relating to production and analysis of mRNA; technological advisory services relating to production and analysis of mRNA; research and development relating to gene therapy; technical advisory services relating to gene therapy research; technological advisory services relating to productization of gene therapy products; research and development in the fields of bacteriology, cytology, antibody technology, chemistry, immunology, and gene expression systems; scientific research in the fields of genetics and genetic engineering; DNA screening for scientific research purposes; research and development, and technical advisory services relating thereto in the fields of protein, antibody, vaccine, virus, virus vector, mRNA, microorganisms, and cells; structural and functional analysis of the genome with genome synthesis technology; DNA screening for scientific research purposes with genome synthesis technology; research and development relating to genome synthesis technology; technical advisory services relating to genome synthesis technology; research and development, and technical advisory services relating thereto in the fields of protein, vaccine, virus, virus vector, mRNA, antibody, microorganisms, and cells, all with genome synthesis technology; research and development in the fields of bacteriology, cytology, antibody technology, chemistry, immunology, and gene expression systems, all with genome synthesis technology; scientific research in the fields of genetics and genetic engineering with genome synthesis technology; testing, inspection, and research of pharmaceuticals, gene therapy products, regenerative medical products, cosmetics or foodstuffs, all with genome synthesis technology; development of pharmaceuticals, gene therapy products, regenerative medical products, cosmetics or foodstuffs, all with genome synthesis technology; technical advisory services relating to development of pharmaceuticals, gene therapy products, regenerative medical products, cosmetics or foodstuffs, all with genome synthesis technology; quality testing, inspection, and research relating to medical treatment or medical technology with genome synthesis technology; testing and research relating to genome or gene to which genome synthesis technology is applied; research and development for the pharmaceutical industry and biotechnology industry with genome synthesis technology; research and development relating to biotechnology for others; research and development relating to genome synthesis technology for others; research and development relating to production and analysis of virus vector for others; research and development relating to gene therapy products for others; biotechnology research; research and development in the fields of genomics and biotechnology; technical advisory services in the fields of genomics and biotechnology; structural and functional analysis of genomes; quality testing, inspection, and research in the fields of agriculture, livestock breeding or fisheries; development of pharmaceutical preparations and medicines; product development for others; research and development of new products for others; development of new technology for others in the fields of genomics and biotechnology; research and development of genome synthesis technology for others; research and development of new products for others with DNA synthesis technology; research and development in the field of gene expression systems; research and development in the fields of microorganisms and cells; research and development of microorganisms for others; research and development of microorganisms which produce useful substances for others; bacteriological research; biological research
Owner
Prosecution history
- 27 Jun 2024 — FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
- 28 May 2024 — REGISTERED-PRINCIPAL REGISTER
- 12 Mar 2024 — NOTIFICATION PROCESSED BY IB
- 12 Mar 2024 — PUBLISHED FOR OPPOSITION
- 21 Feb 2024 — NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
- 21 Feb 2024 — NOTICE OF PUBLICATION
- 21 Feb 2024 — NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
- 01 Feb 2024 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 27 Dec 2023 — ASSIGNED TO EXAMINER
- 27 Jun 2023 — APPLICATION FILING RECEIPT MAILED
- 23 Jun 2023 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 22 Jun 2023 — SN ASSIGNED FOR SECT 66A APPL FROM IB